Abstract:Purpose: Reduced expression of the transforming growth factor 0 receptor type II (TGFbetaRII), a key inhibitor of epithelial cell growth and tumor suppressor gene, was reported frequently in many types of tumors including non-small cell lung cancer (NSCLC). This study explored the significance of the TGFbetaRII gene in NSCLC carcinogenesis.Experimental Design: With 43 independent pairs of tumor and paracarcinoma tissue samples from patients with primary NSCLC, we carried out PCR-denaturing gradient gel electrophoresis screening for DNA variants over the coding sequence of the TGFbetaRII gene, immunohistochemical assay of TGFbetaRII expression, methylation-specific PCR analysis, and semiquantitative reverse transcription-PCR.Results: The PCR-denaturing gradient gel electrophoresis did not detect variation in the whole coding sequence of the TGFbetaRII gene, but the immunohistochemistry experiment revealed reduced or lost expression of the gene in 44% (19 of 43) of the tumor samples. The methylation analysis on the 19 pairs detected the frequent occurrence of methylated TGFbetaRII promoter in tumor tissues, whereas most of the paracarcinoma tissues were free of methylation. The reduced TGFbetaRII expression was highly significantly associated with the methylation event (P < 10(-4)). The reverse transcription-PCR analysis demonstrated a clear agreement between reduced TGFbetaRII expression and decreased mRNA level of the gene in the tumor tissue samples.Conclusions: TGFbetaRII plays an important role as a tumor suppressor in NSCLC carcinogenesis. The defective expression may serve as one of most important molecular mechanisms in explaining progression of the disease. In particular, aberrant 5' CpG methylation of the gene has explained the down-regulation of the gene at a transcriptional level.

Supplementary Figure 2 from CMTM3, Located at the Critical Tumor Suppressor Locus 16q22.1, is Silenced by CpG Methylation in Carcinomas and Inhibits Tumor Cell Growth Through Inducing Apoptosis

Data from <i>CMTM3</i>, Located at the Critical Tumor Suppressor Locus 16q22.1, Is Silenced by CpG Methylation in Carcinomas and Inhibits Tumor Cell Growth through Inducing Apoptosis

Cmtm3, Located At The Critical Tumor Suppressor Locus 16q22.1, Is Silenced By Cpg Methylation In Carcinomas And Inhibits Tumor Cell Growth Through Inducing Apoptosis

Association of Abnormal Methylation of CpG Islands in Promoter Domains of Multiple Tumor Suppressor Genes with Non-Small Cell Lung Cancer

CMTM3 Inhibits Human Testicular Cancer Cell Growth Through Inducing Cell-Cycle Arrest and Apoptosis

TET1 Suppresses Cancer Invasion by Activating the Tissue Inhibitors of Metalloproteinases.

A Novel 3p22.3 Gene CMTM7 Represses Oncogenic EGFR Signaling and Inhibits Cancer Cell Growth

Epigenetic identification of CHD5 as a critical 1p36.3 tumor suppressor frequently inactivated by promoter methylation in multiple carcinomas

CMTM5 Exhibits Tumor Suppressor Activities and is Frequently Silenced by Methylation in Carcinoma Cell Lines

The 3p14.2 Tumour Suppressor ADAMTS9 is Inactivated by Promoter CpG Methylation and Inhibits Tumour Cell Growth in Breast Cancer.

Defective Expression Of Transforming Growth Factor Beta Receptor Type Ii Is Associated With Cpg Methylated Promoter In Primary Non-Small Cell Lung Cancer

Supplementary Figure 1 from DNA Methylation-Mediated Repression of Mir-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Supplementary Figure 2 from Progressive Chromatin Repression and Promoter Methylation of CTNNA1 Associated with Advanced Myeloid Malignancies

Opcml Is A Broad Tumor Suppressor For Multiple Carcinomas And Lymphomas With Frequently Epigenetic Inactivation

Retraction Notice To: Tumor-Suppressive MicroRNA-216b Binds to TPX2, Activating the P53 Signaling in Human Cutaneous Squamous Cell Carcinoma

Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation

Supplementary Figure 3 from Global Hypomethylation of Genomic DNA in Cancer-Associated Myofibroblasts

DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs

Supplementary Figure 1 from Progressive Chromatin Repression and Promoter Methylation of CTNNA1 Associated with Advanced Myeloid Malignancies

Supplementary Figure 7 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Supplementary Figure 2 from Global Hypomethylation of Genomic DNA in Cancer-Associated Myofibroblasts